Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report published on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

Galmed Pharmaceuticals stock opened at $2.62 on Friday. Galmed Pharmaceuticals has a one year low of $2.56 and a one year high of $23.80. The business’s fifty day moving average is $2.93 and its 200 day moving average is $3.70. The stock has a market capitalization of $1.69 million, a PE ratio of -0.16 and a beta of 0.66.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.